Cancer Proteomics Agenda

Registration

Identification of a Prognostic Protein Profile for Triple Negative Breast Cancer
Arzu Umar, Group Leader, Erasmus Medical Center Rotterdam/Josephine Nefkens Institute, Netherlands

Triple negative breast cancer is very aggressive and no targeted therapies are currently available. We have performed comparative proteome analysis and identified a 15-protein predictor that associates with patient outcome.

Serum Molecular Portraits – Solving the Puzzle of Cancer
Carl Borrebaeck, Professor and Deputy Vice Chancellor, Lund University, Sweden

One of the driving forces in personalized medicine is the search for protein patterns that can be utilized for improved diagnosis, assessing the risk for tumor relapse and disease progression, as well as for evidence based therapy selection. We have designed and developed antibody microarray, a high-throughput technology for protein expression profiling, to the point where it is now generating data for improved diagnosis, patient stratification, risk assessment, as well as giving insights into disease biology. Several clinical studies have been performed, including analysis of serum/plasma/tissue proteomes from patients suffering from e.g. breast cancer, glioblastoma multiforme, pancreatic carcinoma, gastric adenocarcinoma, chronic lymphocytic leukemia, and Non-Hodgkin lymphomas. The presentation will be focusing on prognostication and risk classification of metastatic breast cancer.

Kinase Centric Chemical Proteomics Provides Novel Insights into Individual Cancer Biology
Bernhard Kuster, Head, Technical University of Munich, Germany

This presentation focuses on chemical proteomics based on small molecule kinase inhibitor probes and quantitative mass spectrometry to understand individual tumour biology and to identify novel potential drug targets and molecular signalling pathway biomarkers.

Coffee Break & Networking in Exhibition Hall

Proteomic Identification of Putative Biomarkers of Radiotherapy Resistance
Lynn Cawkwell, Senior Lecturer, University of Hull, United Kingdom

Putative biomarkers of radiotherapy resistance have been identified using 3 complementary proteomic platforms. Comparisons between gel-based versus gel-free MS approaches and MS versus non-MS approaches will be highlighted. Progress towards the clinical validation of key proteins will be described.

Secretome Proteomics for Tumor Biomarker Discovery
Josep Villanueva, Group Leader, Vall d'Hebron Institute of Oncology, Spain

Cancer secretomes are a promising source of tumor biomarkers. The optimization and implementation of secretome proteomics analysis to different cancer research challenges will be presented.

Lunch & Networking in Exhibition Hall

Poster Viewing Session

Characterization of the Metastatic Secretome of Colorectal Cancer
Jose Alvarez, Staff Scientist, Center for Biological Investigation, Spain

Colorectal cancer is the second cause of cancer-associated mortality in developed countries. Tumor metastasis depends on different factors, such as growth factors and receptors, proteases, chemokines and extracellular matrix proteins. Many of these factors are secreted by the metastatic cells.

Coffee Break & Networking in Exhibition Hall

Label-Free Mass Spectrometry-Based Proteomics for Cancer Biomarker Discovery and Validation
Connie Jimenez, Head, VU University Medical Center, Netherlands

Label-free mass spectrometry-based proteomics has emerged as a powerful tool for biomarker discovery in biological samples. In my lecture, will present our progress in the discovery and validation of novel screening markers for colorectal cancer and the novel breast cancer signature that selects for homology-repair deficient tumors.

Clinical Proteomics in Renal Cancer
Peter Selby, Professor of Cancer Medicine, Leeds Institute of Molecular Medicine, United Kingdom

The urgent clinical need for biomarkers for the diagnosis, prognosis, follow up and prediction of response to therapy in renal cancer can be addressed using label-free quantification mass spectrometry and other approaches.  Recent progress will be summarised.

Drinks Reception

Results From Serum-Tumorautoantibody Profiling of Breast, Colon, Lung and Prostate Cancers Using a 16k Protein Array for Improving Minimal Invasive Diagnostics
Andreas Weinhaeusel, Senior Scientist, Austrian Institute of Technology GmbH, Austria

Using an in house established 16k protein-microarray autoantibody profiling enabled >90% correct classification of patients versus controls using serum- and plasma. Several classifier antigens panels have been defined which are biomarker candidates for minimal invasive early cancer diagnostics.

The Human Protein Atlas
Fredrik Ponten, Professor, Uppsala University, Sweden

Analysis of tissue-specific expression at both the transcript and protein level is vital for understanding human biology and disease. The Human Protein Atlas project employs an antibody-based proteomics approach to systematically map the distribution and relative abundance of human proteins in a multitude of human normal tissues, cancer and cells.

Coffee Break & Networking in Exhibition Hall

Proteomic Analysis of Pathways Involved in Hematophoeisis and Leukaemic Transformation
Anthony Whetton, Professor, Manchester University, United Kingdom

Research on the relationship between mRNA expression and proteomic changes in early hematopoiesis and leukaemic transformation will be presented. A mechanism for the post-translational regulation of protein levels in hematopoietic cells, and the effects of leukaemogenic tyrosine kinases thereon, will be discussed.

In vivo SILAC-based Proteomics Reveals Phosphoproteome Changes during Skin Carcinogenesis
Sara Zanivan, Group Leader, Beatson Institute for Cancer Research, United Kingdom

We show that combining mouse model of carcinogenesis with high resolution mass spectrometry and SILAC mouse technology is powerful strategy to profile accurate phosphoproteomic changes and discover molecules and mechanisms in carcinoma development.

Lunch & Networking in Exhibition Hall

Poster Viewing Session

Proteomics of Triple-negative Breast Cancer
Metodi Metodiev, Biological Safety Officer, University of Essex, United Kingdom

The talk will present mechanistic studies of triple-negative breast cancer utilizing high-resolution label-free mass spectrometry of tumor biopsies and SILAC-based large - scale phosphorylation site analysis of cultured cancer cells.

Coffee Break & Networking in Exhibition Hall

Modeling Signalling Networks Involved in Carcinogenesis
Emmanuel Barillot, Bioinformatics and IT Director, Institut Curie, France

The subject of the presentation will deal with several approaches we have implemented for investigating how a biological network can control cellular processes in cancer, and give rise to tumorigenesis, tumor progression, or therapeutic response or resistance. In particular we are interested in predicting the fate of cells or tumors upon different perturbations (either genetic, chemical or other): death, proliferation, invasion, metastasis...

Proteomic and Bioinformatic Approaches to the Development of Biomarker Signatures of Clinical Utility for Prostate Cancer: From Discovery to Targeted Verification
Stephen Pennington, Professor, University College Dublin, Ireland

Prostate cancer (PCa) is the most common male cancer and third leading cause of cancer deaths among men in western world. Current tests for PCa have limited predictive capabilities. We have undertaken a label-free LC-MS/MS and MRM workflow for the discovery and verification of biomarker signatures of potential clinical utility for PCa patient management.

Close of Conference